glucose lowering for cardiovascular prevention

systematic review meta-analysis network meta-analysis

Select diabetes type 2 All type of patientuncoded clinical condition ***       DPP-4 inhibitorsglucagon-like peptide 1 receptor agonistinduced HbA1c reductioninsulinPPAR modulatorSGLT2 inhibitorsthiazolidinediones aleglitazarertugliflozinsemaglutidealogliptincanagliflozindapagliflozinempagliflozinexenatideglarginelinagliptinliraglutidelixisenatide pioglitazonesaxagliptinsitagliptin vs placebovs SU      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	Cardiovascular death (40)cardiovascular events (39)All cause death (38)stroke (fatal and non fatal) (31)myocardial infarction (fatal and non fatal) (28)macrovascular events (18)Non fatal MI (11)microvascular events (10)hospitalisation for heart failure (10)Fatal MI (7)nephropathy (6)macrovascular or microvascular events (5)Non fatal stroke (5)retinopathy (4)Amputations (4)all cause death, MI, stroke (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	Cardiovascular death	cardiovascular events
diabetes type 2
aleglitazar
ALEPREVENT	aleglitazar	placebo			Low risk of bias	-
ALECARDIO, 2014      NCT	aleglitazar	placebo			Low risk of bias	negative
alogliptin
EXAMINE, 2013      NCT	alogliptin	placebo			Low risk of bias	negative
canagliflozin
CANVAS, 2017            NCT	canagliflozin	placebo			Low risk of bias	conclusive
dapagliflozin
DECLARE TIMI 58, 2018        NCT	dapagliflozin	placebo			Low risk of bias	-
empagliflozin
EMPA-REG OUTCOME, 2015      NCT	empagliflozin	placebo			Low risk of bias	conclusive
exenatide
EXSCEL, 2017    NCT	exenatide	placebo			Low risk of bias	conclusive
glargine
ORIGINE, 2012      NCT	insulin glargine	control				negative
linagliptin
CAROLINA, 2012      NCT	linagliptin	glimepiride			Low risk of bias	suggesting
liraglutide
LEADER, 2016      NCT	liraglutide	placebo			Low risk of bias	conclusive
lixisenatide
ELIXA          NCT	lixisenatide	placebo			Low risk of bias	negative
pioglitazone
PROACTIVE      NCT	pioglitazone	placebo				-
IRIS, 2016      NCT	pioglitazone	placebo				-
saxagliptin
SAVOR TIMI, 2013      NCT	saxagliptin	placebo			Low risk of bias	negative
semaglutide
SUSTAIN 6, 2016      NCT	semaglutide	placebo			Low risk of bias	conclusive
sitagliptin
TECOS, 2015          NCT	sitagliptin	placebo			Low risk of bias	negative